Comparative Risk Assessment of Severe Uterine Bleeding Following Exposure to Direct Oral Anticoagulants: A Network Study Across Four Observational Databases in the United States
=============

<img src="https://img.shields.io/badge/Study%20Status-Results%20Available-yellow.svg" alt="Study Status: Results Available"> 

- Analytics use case(s): **Population-Level Estimation**
- Study type: **Clinical Application**
- Tags: **DOACs**
- Study lead: **James Weaver**
- Study lead forums tag: **[jweave17](https://forums.ohdsi.org/u/jweave17), [Azza_Shoaibi](https://forums.ohdsi.org/u/azza_shoaibi)**
- Study start date: **April 13, 2020**
- Study end date: **-**
- Protocol: **[PDF](https://github.com/ohdsi-studies/DoacsWarfarinSub/tree/master/Protocol)**
- Publications: **-**
- Results explorer: **[Shiny app](https://data.ohdsi.org/DoacsWarfarinSub/)**

This study evaluated the comparative risk of severe uterine bleeding for rivaroxaban, apixaban, dabigatran, and warfarin therapies among propensity score-matched patients with non-valvular atrial fibrillation and venous thromboembolism in routine clinical practice. The study was registered at https://clinicaltrials.gov/ct2/show/NCT04394234.